Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZBX - Genzyme Biosurgery -- Ignore unavailable to you. Want to Upgrade?

To: Extra Pale who wrote (14)	1/15/2002 12:21:49 AM
From: Spekulatius	Read Replies (1) \| Respond to of 18

GZBX has a cash burn of about 20M$ per quarter. They have about 40M$ in cash plys 17M$ in undrawn credit from GENZ. While they their cash burn rate might decrease, i don't really think that they have enough cash on hand to last to cash flow break even. I guess they assume that the shares are undervalued and will trade higher in future, a risky assumption IMO. I agree that GZBX is undervalued but I dislike the shareholder unfriendly management, so I currently have no position but would consider to buy at less than 4 1/2$.